Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
Hiroji Uemura, Hisashi Matsushima, Kazuki Kobayashi, Hiroya Mizusawa, Hiroaki Nishimatsu, Karim Fizazi, Matthew Smith, Neal Shore, Teuvo Tammela, Ken ichi Tabata, Nobuaki Matsubara, Masahiro Iinuma, Hirotsugu Uemura, Mototsugu Oya, Tetsuo Momma, Mutsushi Kawakita, Satoshi Fukasawa, Tadahiro Kobayashi, Iris Kuss, Marie Aude Le BerreAmir Snapir, Toni Sarapohja, Kazuhiro Suzuki
Research output: Contribution to journal › Article › Scientific › peer-review
15Citations
(Scopus)
13Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial'. Together they form a unique fingerprint.